It’s this kind of receptive, genius thinking that’s been pushing boundaries at Spiderwort, an Ottawa-based startup developing biomaterials to repair and regenerate the human body. The team’s innovative theories will one day treat people with spinal cord injuries, and we have their enduring curiosity, an apple and a bunch of asparagus to thank.
Originally published in Ottawa Founders, Ottawa Business Journal , a column prepared by the Capital Angel Network celebrating CAN Portfolio leaders envisioning the future.
By Suzanne Grant
After the apple experiment, Pelling was at home cutting spears of asparagus for dinner and wondered if its vascular bundles (tube-like tissues) could be used to repair spinal cord injuries. The idea was to implant part of the asparagus into damaged areas of the spinal cord to act as a bridge and help neurons reconnect. When they tested asparagus fibres in rats, they once again saw incredible results—rats that were paralyzed from the waist down started moving their legs within 10 weeks. “I’ll always remember the night we were observing the animals and some of them started showing movement. We knew the body was accepting the material, and this suggested the same thing could help humans,” he says.
Spiderwort was officially founded in 2015 and, in subsequent years, their proprietary plant-based scaffolding and technology have resulted in two products—the first is CelluBridge, which is a solid (the scaffold) that’s implanted in the spinal cord and works to repair and regenerate the tissue. (It was recognized by the U.S. Food and Drug Administration as a breakthrough medical device in 2019.) The other is CelluJuve, a cellulose-based dermal filler (in hydrogel form) that’s much easier to use—it’s injected under the skin and is mostly for cosmetic enhancement, like smoothing wrinkles or repairing skin deformations. “These two products are on either side of the spectrum—one is high-risk and high-return and has the ability to cure a condition that hasn’t been cured yet. The other is also high-return but it’s lower-risk,” says Cuerrier. “We believe there are many other things we can work on between these two extremes. We’ve opened a new category of biomaterial. Cellulose has been used in the past, but not in the way we’re using it. This is about the structure of cellulose Mother Nature created.”
The continuous success of their repeated trials (they’ve done countless experiments to validate their results) hasn’t just impressed pathologists, but their findings have also struck a chord with angel investors across the country—and certainly not just from angels who have medical backgrounds. “We have had so many good people support us up front. Angels saw potential and believed in us. It seems like a crazy idea to use asparagus cellulose in humans, but they helped us close our friends-and-family round and good things have happened for our team since,” he says, adding angels from his local angel group, Capital Angel Network (CAN), have been enthusiastic champions. “I don’t think I’d ever start another company without involving angel investors. Other investors are supportive, but founders have a unique relationship with angels. I can email or call an angel from CAN—even one who didn’t invest in us but has experience we need—and they’re always willing to help.” And because the ecosystem has been so supportive of Spiderwort, Cuerrier shares his knowledge by offering advice and guidance to other startups. “This is especially important in the medical community, when you’re saving lives.”
More than eight years in, Cuerrier and his growing team (there are 25 employees now) continue to move their work forward. Getting a medical device into the hands of surgeons is no easy feat. CelluBridge will likely be in clinical trials this year, and the product will be put into about a dozen patients who have spinal cord injuries. After, there will be even more studies before going to market. The process is long and arduous—every detail must be examined and validated by third parties (other scientists) and regulating bodies (Health Canada and the U.S. Food and Drug Administration) before a medical device can be used. “We are about to show that our products are safe. We’ve done so many safety studies, and we’re able to show the world we have something that’s not only effective, but it’s also safe for humans. We must be sure it’s top-notch, and that’s what we’ve done over the last few years,” he says. “Finally saying we’re going to be in clinic this year is a great feeling.”
As someone who grew up around entrepreneurs, Cuerrier now recognizes being a founder is much like being a scientist. “There’s a problem you’re passionate about, and whether it ends up being a product or service that can help, your goal is to fix it,” he says. “In this case, the material we’re using is like magic.” (In fact, Spiderwort’s sister company, Whiteboard Foods, is using the same technology to enhance sustainable plant-based meats, cultured meats and alternative proteins.) “Not only does an apple a day keep the doctor away, but it can also heal and repair the human body. That’s incredible.”
Suzanne Grant is an entrepreneur who has built bootstrapped and equity-financed businesses in Canada, Australia and Qatar. Today, she supports business growth and positioning while sharing insights to demystify early-stage fundraising. Grant leads the Capital Angel Network as executive director.